Solx, Inc. is a Waltham, MA-based medical device company focused on surgical technologies to treat glaucoma and preserve vision. Its lead product, the SOLX Gold Shunt™, is an implantable drainage device designed to reduce elevated intraocular pressure without creating a bleb. The device routes aqueous humor from the anterior chamber to the suprachoroidal space, utilizing a natural pressure differential within the eye. The SOLX Gold Shunt has regulatory approval in Canada and Europe and has been tested in a multi-center clinical trial. In the U.S. the device remains investigational and is awaiting FDA approval. The company is led by President and CEO Kevin McMahon and is backed by MVM Life Science Partners, River Street Management, Easton Capital, and other institutional investors. Solx is a Waltham, Mass.-based medical device company focused on the Gold Shunt. The Gold Shunt is a 24-karat gold micro-implant designed to reduce the intra-ocular pressure caused by glaucoma by using the natural pressure differential between the front and back of the eye. The device won clearance from Health Canada. Solx sold exclusive Canadian rights for the device to I-MED Surgical in 2010. The company has been actively raising capital, adding $2.1M in an options and debt round and having raised $3.3M earlier this year. It is currently seeking around $4.8M in funding. SOLX develops surgical treatments and management approaches for glaucoma. The company is privately held and positions itself as an emerging leader in glaucoma management and surgical care. SOLX was founded in 2000 by a serial ophthalmology entrepreneur. The firm is financially backed by MVM Life Science Partners. SOLX recently raised $3.3 million in a venture capital financing disclosed in an SEC filing. The filing notes three separate investors participated in the offering.

Total raised

$5M

Funding rounds

3

Latest round

Debt Financing

Latest activity

Dec 2013